This is a US news story, published by UNSW Sites, that relates primarily to FDA news.
For more US news, you can click here:
more US newsFor more mental health treatments news, you can click here:
more mental health treatments newsFor more news from UNSW Sites, you can click here:
more news from UNSW SitesOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about
ketamine tablets. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Ketamine news, other antidepressant medications news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
ketamine treatmentUNSW Sites
•78% Informative
A slow-release tablet form of ketamine with minimal side effects has the potential to make treatment more affordable and accessible.
Patients on the strongest dose at 180 mg, taken orally twice a week, had the best results when compared with placebo.
The next step is to get the drug approved by the FDA in the US or the New Zealand .
VR Score
75
Informative language
73
Neutral language
61
Article tone
informal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
1
Source diversity
1
Affiliate links
no affiliate links